- Recent news related to acute myeloid leukemia (AML) includes the FDA approval of two treatments:
- Quizartinib (Vanflyta®) in combination with standard chemotherapies for newly diagnosed AML patients with the FLT3-ITD genetic mutation1.
- Daurismo (glasdegib) tablets in combination with low-dose cytarabine (LDAC) for newly-diagnosed AML in adults who are 75 years of age or older or have other chronic health conditions2.
Learn more:✕This summary was generated using AI based on multiple online sources. To view the original source information, use the "Learn more" links.Rye Brook, N.Y., July 25, 2023 – The U.S. Food and Drug Administration (FDA) last week approved quizartinib (Vanflyta®) in combination with standard chemotherapies for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that carries a genetic mutation called FLT3-ITD.www.lls.org/news/fda-approves-new-targeted-treat…The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are 75 years of age or older or who have other chronic health conditions or diseases (comorbidities) that may preclude the use of intensive chemotherapy.www.fda.gov/news-events/press-announcements/f… - People also ask
Revumenib Shows Promise for Advanced Acute Myeloid Leukemia
Many new treatments that have been developed, such as ivosidenib (Tibsovo) and midostaurin (Rydapt), target genetic changes thought to drive some forms of AML. But resistance to these drugs tends to develop relatively quickly. And each of the gene changes targeted by these drugs are found in only a minority of … See more
The phase 1 AUGMENT-101 trial—which was funded by Syndax Pharmaceuticals, the maker of revumenib—was the first to test the new drug in people. It was designed to test the drug’s safety and find the best dose for future, larger trials. In total, 60 adults and 8 … See more
For some participants in AUGMENT-101, their cancers rapidly developed resistance to revumenib. In a companion study published in the … See more
The first generation of menin inhibitors shows promise in early trials. But Dr. Cai hopes that the structural information his team gathered may … See more
Latest advancements in treatment for acute myeloid leukemia
WEBMar 2, 2023 · Learn about the latest advancements in chemotherapy, targeted therapy and immunotherapy for acute myeloid leukemia (AML), a rapid and serious blood cancer. …
FDA Approves New Targeted Treatment for Acute …
WEBRye Brook, N.Y., July 25, 2023 – The U.S. Food and Drug Administration (FDA) last week approved quizartinib (Vanflyta®) in combination with standard chemotherapies for the treatment of adult patients with newly …
ImCheck Receives FDA Fast Track Designation for ICT01 in …
WEBMarseille, France, September 18, 2024 – ImCheck Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ICT01 …
New combinations and targeted therapies for acute myeloid …
WEBDec 11, 2023 · Acute myeloid leukemia is a cancer characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with normal …
Acute myeloid leukemia: current progress and future directions
WEBFeb 22, 2021 · Abstract. Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been …
FDA Grants Fast Track Designation to ICT01 in Combination With ...
WEB4 days ago · ICT01 (ImCheck) in combination with azacitidine (Vidaza; Bristol-Myers) and venetoclax (Venclexta; AbbVie Inc) has been granted a fast track designation for the …
New CAR T Cell Clinical Trial for Acute Myeloid …
WEBApr 22, 2024 · Acute myeloid leukemia (AML) is one of the most challenging blood cancers. The disease moves quickly and needs aggressive treatment with chemotherapy, sometimes followed by a bone …
Transplantation and long-term overall survival in acute myeloid ...
WEB1 day ago · Two thirds of patients with acute myeloid leukaemia are older than 60 years and have poor long-term survival. Although new front-line therapies, such as venetoclax …
Recommendations from the AML molecular MRD expert advisory …
WEBMay 23, 2024 · The standard-of-care treatment for patients with acute myeloid leukemia (AML) is being challenged by new classes of targeted therapies, including FLT3, IDH …
